Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00772603 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00772603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00772603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2008
Completion date
November 30, 2010
Enrollment
366 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsies, partial